



The Maryland State Medical Society
1211 Cathedral Street
Baltimore, MD 21201-5516
410.539.0872
Fax: 410.547.0915
1.800.492.1056
www.medchi.org

Senate Finance Committee
February 12, 2026

Senate Bill 78 – *Public Health – Prostate-Specific Antigen Testing (Protect Our Prostate Act)*

POSITION: OPPOSE

The Maryland State Medical Society (MedChi), the largest physician organization in Maryland, **opposes** Senate Bill 78.

Senate Bill 78 proposes several new requirements governing how health care providers and clinical laboratories administer, disclose, and report prostate-specific antigen (PSA) test results. Specifically, providers and laboratories must provide the patient with written information on the necessary preparation to ensure accurate test results. The bill also includes specific requirements for clinical laboratories that perform PSA tests.

While MedChi strongly supports the importance of PSA testing, we question whether the bill is necessary given that PSA testing is already guided by evidence-based recommendations from nationally recognized organizations, including the American Urological Association, including when testing is recommended and appropriate patient counseling prior to PSA testing. The standard of care already includes shared physician-patient decision-making regarding PSA testing, making the new statutory mandates under this bill redundant. Furthermore, we are concerned that additional requirements for providers and labs may create confusion among patients and lead to reluctance to undergo this critically important testing and discourage appropriate screening from taking place. We are also concerned that the additional requirements may discourage some providers from ordering appropriate screening to avoid violating the new law. Instead, we believe that patients with an elevated PSA should continue to consult their physician or urologist for appropriate counseling and shared decision-making regarding necessary follow-up steps.

We share the sponsor's concern about the evaluation and management of PSA testing and prostate cancer, but believe this bill is duplicative, and the additional requirements are potentially detrimental. For these reasons, MedChi urges an unfavorable report on Senate Bill 78.

For more information call:

Andrew G. Vetter
J. Steven Wise
Danna L. Kauffman
Christine K. Krone
410-244-7000